NAD+ & NMN for Eye Health (Glaucoma, AMD): The Evidence
Nicotinamide glaucoma trials show short-term retinal-function signals, not proven protection from blindness. Review the endpoints, liver risks and NMN evidence.
Updated
6 min read · 12 sources
On this page
If you search "NAD+ for eyes," you'll hit two very different worlds. One is a genuine, randomized-trial story about a specific form of vitamin B3 protecting the optic nerve in glaucoma. The other is supplement marketing that quietly borrows that credibility to sell NMN capsules for "eye health," macular degeneration, and "vision longevity" — claims the human evidence does not support. The honest version separates them carefully, because they are not the same molecule, not the same disease, and not the same level of proof.
Here's the one-line version to anchor everything below: in glaucoma, nicotinamide (a form of vitamin B3) has real human randomized-trial evidence for improving the optic nerve's function — but for age-related macular degeneration (AMD), and for NMN specifically, the supportive data are still animal and cell-culture only.
Featured partner
CoreAge Rx
From $93/mo
Check availabilityRead our reviewAffiliate link. We may earn a commission at no extra cost to you.
Affiliate partner
RxSpan MD
Physician-led NAD+ & longevity telehealth
See RxSpan MDWhy the eye is an NAD+ story at all
The retina is, gram for gram, one of the most metabolically demanding tissues in the body. The retinal ganglion cells — whose long axons bundle together to form the optic nerve — are packed with mitochondria and burn through enormous amounts of energy to keep firing. That makes them exquisitely dependent on NAD+, the central coenzyme of mitochondrial energy production, and unusually vulnerable when NAD+ supply falls. The foundational demonstration came from a 2017 mouse study in Science: in aged mice genetically prone to glaucoma, retinal NAD+ declined with age, and supplementing nicotinamide (vitamin B3, an NAD+ precursor) robustly protected the retinal ganglion cells and prevented glaucoma from developing 1. Follow-up mechanistic work confirmed the throughline — nicotinamide guards these neurons against the mitochondrial and metabolic dysfunction that drives their death 5, and reviews now frame the NAD+/NADH redox state as both a candidate biomarker and a therapeutic target in glaucoma 6.
Why the optic nerve is an NAD+ story
Retinal ganglion cells
Mitochondria-rich; form the optic nerve
Retinal NAD+ declines with age
Less fuel for these high-demand neurons
Mitochondrial vulnerability
Drives glaucomatous cell death (mouse)
Nicotinamide repletion
Protected the nerve in aged mice → tested in humans
That biology is legitimate, and unlike most "NAD+ for X" pitches, it has actually been carried into human trials for one disease.
Glaucoma: where the human RCT evidence is real
This is the strong part of the story, and it deserves to be stated plainly. Nicotinamide has been tested in randomized, placebo-controlled human trials in glaucoma, and it improved a measure of how well the inner retina works.
In a crossover randomized trial, nicotinamide improved an electrical measure of inner-retinal function while participants continued pressure-lowering care 2. The Phase 2 nicotinamide-plus-pyruvate trial then found more improving visual-field test locations; it did not find significant improvement in mean deviation or visual-field index. Only 32 participants completed that trial, with a median follow-up of about 2.2 months 3. A 2026 post-hoc analysis revisited those same 32 eyes, so it is further analysis rather than an independent replication 12.
The 2026 normal-tension glaucoma crossover trial enrolled 53 participants and tested 1 g/day followed by 2 g/day of nicotinamide in each 12-week treatment period. Some retinal electrical responses improved, but mean deviation, pattern standard deviation and visual-field index did not differ significantly between treatment and placebo 4. Its design crossed participants over without a washout period, another reason to distinguish a promising short-term signal from proven long-term neuroprotection.
A six-month study reported quality-of-life changes 10, but patient reports do not establish prevention of sight loss.
Read together, these are the rare case where the NAD+ supplement story has actual randomized human evidence behind it. But the caveats matter for honesty:
- The doses are pharmacological. The American Glaucoma Society and American Academy of Ophthalmology advise against 3 g/day or more outside closely monitored clinical trials because of liver-injury risk. Even lower-dose use for glaucoma calls for physician coordination and liver-function monitoring 11.
- The endpoints so far are function measures (inner-retinal electrophysiology, visual-field metrics over months), not yet proof that nicotinamide prevents long-term blindness or replaces pressure-lowering therapy.
- In every trial, nicotinamide was added on top of standard glaucoma treatment — it is an adjunct under study, not a standalone cure.
Eye-health claims readout
- Nicotinamide → inner-retinal function (glaucoma)Moderate evidence
Crossover randomized trial; improved electrophysiological inner-retinal function on top of pressure-lowering therapy.
- Nicotinamide + pyruvate → visual field (open-angle glaucoma)Moderate evidence
32 completers; more improving test locations, but no significant mean-deviation or visual-field-index benefit. Combination treatment, not isolated nicotinamide.
- Nicotinamide in normal-tension glaucomaModerate evidence
2026 crossover trial: improved electrical responses, but no significant between-group difference in visual-field global indices.
- NMN / NAD+ → AMD / macular vision in peopleNone evidence
Animal RPE and photoreceptor models only. No human outcome trial. AREDS2 — not NAD+ — is the human-evidenced AMD formula.
So the accurate framing is: nicotinamide has preliminary retinal-function signals in glaucoma, with mixed visual-field results and no established long-term protection from sight loss — but it is still investigational, dosed in gram quantities, and not a substitute for seeing an ophthalmologist.
AMD and the retina: real biology, animal-only data
Now the part the marketing blurs. Age-related macular degeneration is a different disease — degeneration of the macula and retinal pigment epithelium (RPE), not the optic nerve — and here the NAD+ evidence drops a full tier, to animals and cells.
The mechanistic rationale is real: NAD+ supports the highly energy-dependent photoreceptors and RPE, and in a mouse model, NAD+ maintenance attenuated light-induced photoreceptor degeneration 8. For the RPE specifically, nicotinamide mononucleotide (NMN) reduced cellular senescence and inflammation in a sodium-iodate model of RPE damage used to mimic AMD-like injury 9. Nicotinamide riboside (NR), another precursor, preserved retinal ganglion cells in a glutamate-toxicity cell model 7. These are encouraging — but every one of them is in mice or in a dish. There is no randomized human trial showing that NMN, NR, or NAD+ slows AMD progression, preserves macular vision, or improves any sight outcome in people with macular degeneration. That gap is the entire difference between "biologically plausible" and "proven."
This is also where the molecule swap matters. The human glaucoma trials used nicotinamide (and in one case nicotinamide plus pyruvate) — not NMN. NMN reliably raises blood NAD+ in people, but its eye data are confined to animal RPE and photoreceptor models 9. So a bottle of NMN sold for "eye health" is borrowing evidence that belongs to a different B3 form, used for a different eye disease, at a clinically supervised dose.
What this means if you actually care about your eyes
A few honest takeaways:
- If you have glaucoma — especially normal-tension glaucoma — ask your ophthalmologist how the investigational evidence applies to your situation. Short-term retinal-function findings do not establish slower disease progression 234, and the professional safety statement limits high-dose use because of liver risk 11.
- If your goal is preventing or slowing AMD, the NAD+/NMN evidence is animal-only 89. The thing with actual human AMD trial evidence is the AREDS2 antioxidant formula for selected AMD stages — a separate clinical question to discuss with an ophthalmologist, not evidence for an NAD+ precursor.
- NMN specifically has no human eye-disease trial. Buying NMN for "vision" is acting on mouse RPE data and on glaucoma trials that used a different compound.
Bottom line
The eye is a genuine NAD+ story, but the honest grade splits sharply by disease and by molecule. For glaucoma, nicotinamide has short-term randomized retinal-function findings, while visual-field results are mixed. It remains investigational; these studies do not establish prevention of long-term vision loss 1234. For AMD and the broader retina, and for NMN specifically, the protective data are striking but confined to animals and cell culture 89 — no human outcome trial exists. Treat glaucoma nicotinamide as an investigational option with important liver-safety restrictions to discuss with an eye doctor, and treat NMN-for-vision as unproven marketing. For the broader picture, see our pillar guide to NAD+ therapy, our honest look at whether NAD+ is really anti-aging, the parallel skin story in NAD+ for skin, and where products land in the best NAD+ supplements.
This is consumer education, not medical advice. The glaucoma trials used high pharmacological doses of nicotinamide under medical supervision; do not self-treat any eye disease. If you have glaucoma, macular degeneration, or any vision change, see an ophthalmologist.
Frequently asked questions
Does nicotinamide help glaucoma?
Small trials report short-term retinal electrical-function signals. Visual-field findings are mixed: the 2026 normal-tension study did not find significant changes in global visual-field indices. Prevention of long-term sight loss has not been established, and nicotinamide remains investigational.
Is NMN proven for eye health or macular degeneration?
No convincing human outcome evidence establishes NMN as an eye-disease treatment. Nicotinamide glaucoma trials concern a different B3 molecule and a different disease from macular degeneration.
Is high-dose nicotinamide safe to take for glaucoma?
The AGS and AAO advise against 3 g/day or more outside clinical trials with close liver monitoring because of liver-injury risk. Even lower doses considered for glaucoma require physician coordination and periodic liver testing. Do not select a dose from a supplement claim.
Is the July 2026 visual-field analysis a new independent trial?
The July 2026 topographical analysis re-examined the same 32 study eyes from the earlier nicotinamide-plus-pyruvate Phase 2 trial. It is additional analysis, not independent replication.
Should nicotinamide replace glaucoma drops?
No. The trials studied supplementation alongside established pressure-lowering care. Continue prescribed treatment and consult your ophthalmologist before adding supplements.
References
- Williams PA, Harder JM, Foxworth NE, et al. (2017). Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. https://pubmed.ncbi.nlm.nih.gov/28209901/
- Hui F, Tang J, Williams PA, et al. (2020). Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial. Clinical & Experimental Ophthalmology. https://pubmed.ncbi.nlm.nih.gov/32721104/
- De Moraes CG, John SWM, Williams PA, et al. (2022). Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmology. https://pubmed.ncbi.nlm.nih.gov/34792559/
- Ha A, Kim YK, Jeoung JW, et al. (2026). Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial. British Journal of Ophthalmology. https://pubmed.ncbi.nlm.nih.gov/41167798/
- Tribble JR, Otmani A, Sun S, et al. (2021). Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. Redox Biology. https://pubmed.ncbi.nlm.nih.gov/33932867/
- Petriti B, Williams PA, Lascaratos G, et al. (2021). Neuroprotection in Glaucoma: NAD+/NADH Redox State as a Potential Biomarker and Therapeutic Target. Cells. https://pubmed.ncbi.nlm.nih.gov/34198948/
- Zhang N, et al. (2024). The role of nicotinamide riboside in the preservation of retinal ganglion cells using an in vitro glutamate-induced excitotoxicity model. Experimental Eye Research. https://pubmed.ncbi.nlm.nih.gov/39414125/
- Bai S, Sheline CT (2013). NAD(+) maintenance attenuates light induced photoreceptor degeneration. Experimental Eye Research. https://pubmed.ncbi.nlm.nih.gov/23274583/
- Ren C, et al. (2022). Nicotinamide Mononucleotide Ameliorates Cellular Senescence and Inflammation Caused by Sodium Iodate in RPE Cells. Oxidative Medicine and Cellular Longevity. https://pubmed.ncbi.nlm.nih.gov/35898618/
- Nicola CA, et al. (2025). Changes in Quality of Life Among Glaucoma Patients Following Six Months of Niacinamide Supplementation. Nutrients. https://pubmed.ncbi.nlm.nih.gov/40944166/
- Shukla AG, Cioffi GA, John SWM, et al. (2025). American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection. Ophthalmology Glaucoma. https://pubmed.ncbi.nlm.nih.gov/39800263/
- De Moraes CG, et al. (2026). A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma. Investigative Ophthalmology & Visual Science. https://pubmed.ncbi.nlm.nih.gov/42517851/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Related reading
NMN & NAD+ for Kidney Health (CKD): What's Proven?
Human NR trials in CKD and acute kidney injury measured metabolism, exercise and safety. None establishes NMN as a treatment that preserves kidney function.
ReadNAD+ for Men: Energy, Muscle and Testosterone Evidence
What NAD+ precursor trials in older men show about muscle and function—and why testosterone, ED and fertility claims need different evidence.
ReadNAD+ for Heart Health & Heart Failure: The Evidence
IV NAD+, oral NR, heart failure and blood pressure: what controlled studies measured, which endpoints improved, and what remains unproven.
ReadNAD+ for Brain Fog: What Human Cognition Trials Show
Does NAD+ help brain fog? Compare oral NR cognition trials with claims for injections, and distinguish brain fog from MCI and dementia.
ReadNAD+ Dosage Guide: How Much Per Day, by Form and Route
What the human trials actually used for NR, NMN, niacin and nicotinamide — plus why the tidy injection and IV dosage charts online have no trial behind them.
ReadNAD+ for Women: Benefits, Menopause & What's Proven
NAD+ is marketed to women for energy, menopause, skin and fertility. Here's what the human evidence actually shows — and where it's still just biology.
Read